Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Early Budesonide Intervention for Post-Infectious Cough After Acute Respiratory Infection
ChiCTR2500108820Phase 4Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Sep 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in postinfectious cough and acute respiratory illness (ARI) comparing Experimental group - budesonide inhalation with Placebo group - placebo inhalation (2 arms). Primary endpoint: Proportion of patients with cough at week 8 after treatment. Started Sep 2025; status: recruiting.
02
Drugs
budesonide
03
Conditions
postinfectious coughacute respiratory illness (ARI)
Beyond the preview
Go deeper on ChiCTR2500108820.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108820.